Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$132.80

-7.29 (-5.20%)

14:06
07/12/19
07/12
14:06
07/12/19
14:06

DOJ investigation of J&J 'not new news,' says Raymond James

Raymond James analyst Jayson Bedford said that "technically" it is not "new news" that the DOJ is investigating Johnson & Johnson's communications around the alleged cancer risks of its talcum powder products as J&J previously disclosed an inquiry in its latest 10-Q filing. He notes J&J has responded to a Bloomberg article on the investigation by stating that there have been no new developments, though this risk was "clearly" underappreciated by investors. Though Bedford still thinks J&J has a strong case, today's reaction is an indication that the talc issue will remain "top-of-mind" and a headline risk, he added. Bedford has an Outperform rating on Johnson & Johnson shares.

  • 16

    Jul

  • 09

    Sep

  • 16

    Sep

JNJ Johnson & Johnson
$132.80

-7.29 (-5.20%)

07/11/19
RAJA
07/11/19
NO CHANGE
RAJA
Death of drug rebate rule a win for PBMs and distributors, says Raymond James
After multiple media outlets, including Politico, reported that the Trump Administration has decided to withdraw the drug rebate rule, Raymond James analyst Chris Meekins called the news "a win" for pharmacy benefit managers and drug distributors and "a slight negative" for the pharmaceutical makers. The cost of the proposal to the government was ultimately too high with little guarantee that list prices would go down, said Meekins. However, President Trump hinted something "major" on drug pricing was coming over the next week during his kidney care speech and the analyst thinks the President is planning to move forward with an executive order on pricing. Publicly traded pharmaceutical distributors include McKesson (MCK), Cardinal Health (CAH), Amerisource (ABC) and Patterson (PDCO). Owners of pharmacy benefit managers include CVS Health (CVS), UnitedHealth (UNH), Anthem (ANTM) and Cigna (CI). Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/11/19
JEFF
07/11/19
NO CHANGE
Target $40
JEFF
Buy
Australia implants decision a 'big positive' for Establishment, says Jefferies
After Australia's Therapeutic Goods Administration proposed to cancel or suspend use of textured breast implants, concluding that these devices are associated with a higher rate of anaplastic large cell lymphoma, or ALCL, Jefferies analyst Raj Denhoy called the decision a "big positive" for Establishment Labs (ESTA). The decision is still in the proposal stage, but Establishment is the only manufacturer with products approved in Australia that is not on the list, which proposes to ban implants from Allergan (AGN), J&J's (JNJ) Mentor and other manufacturers, according to Denhoy. He keeps a Buy rating and $40 price target on shares of Establishment Labs.
07/12/19
FBCO
07/12/19
INITIATION
Target $156
FBCO
Outperform
Johnson & Johnson assumed with an Outperform at Credit Suisse
Credit Suisse analyst Matt Miksic assumed coverage of Johnson & Johnson with an Outperform rating and $156 price target. In a research note to investors, Miksic cites key drivers to the rating, including continued growth in Immunology, driven by Stelera and Tremfya, sustainable growth in Oncology driven by Imbruvica, Darzelex and Erleada, an "attractive" pipeline of filings in the 2019-2023 timeframe with greater than$1B potential each, and "stable" growth and cash flows in Medical Devices and Consumer.
07/12/19
WELS
07/12/19
NO CHANGE
Target $29
WELS
Outperform
Australia implant ban 'excellent news' for Establishment Labs, says Wells Fargo
Wells Fargo analyst David Maris believes Australia's proposal to ban, suspend or impose strict restrictions on a number of textured implants from Allergan (AGN), Johnson & Johnson (JNJ) and other smaller manufacturers is "excellent news" for Establishment Labs Holdings (ESTA). The move by Australia's regulatory body Therapeutic Goods Administration will help solidify Establishment's reputation for safety as the company's Motiva brand is the only listed company without any restricted brands, Maris tells investors in a research note. Further, Australia is a highly regulated and developed market, so the ban could help shift market share in other geographies outside of the county as well, contends the analyst. Maris reiterates an Outperform rating on Establishment Labs with a $29 priced target. The stock closed yesterday up $1.54 to $22.44.

TODAY'S FREE FLY STORIES

YGYI

Youngevity

$4.97

-0.22 (-4.24%)

08:40
07/19/19
07/19
08:40
07/19/19
08:40
Hot Stocks
Youngevity's Khrysos Industries closes $19M supply agreement »

Youngevity executed a one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$71.79

0.95 (1.34%)

08:38
07/19/19
07/19
08:38
07/19/19
08:38
Conference/Events
Citi to host conference call »

CFO Mason & Treasurer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Aug

  • 15

    Oct

SYDDF

Sydney Airport

$0.00

(0.00%)

08:37
07/19/19
07/19
08:37
07/19/19
08:37
Initiation
Sydney Airport initiated at JPMorgan »

Sydney Airport initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEAS

SeaWorld

$33.81

0.38 (1.14%)

08:37
07/19/19
07/19
08:37
07/19/19
08:37
Hot Stocks
SeaWorld elects Charles Koppelman as director, announces board changes »

SeaWorld's Board of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

GILD

Gilead

$67.22

0.31 (0.46%)

, NVS

Novartis

$94.30

4.185 (4.64%)

08:37
07/19/19
07/19
08:37
07/19/19
08:37
Hot Stocks
Gilead licenses three preclinical antiviral programs from Novartis »

Gilead (GILD) announced…

GILD

Gilead

$67.22

0.31 (0.46%)

NVS

Novartis

$94.30

4.185 (4.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 22

    Jul

  • 23

    Jul

  • 30

    Jul

  • 07

    Aug

  • 09

    Sep

  • 25

    Sep

BCSF

Bain Capital Specialty Finance

$18.02

-0.06 (-0.33%)

08:35
07/19/19
07/19
08:35
07/19/19
08:35
Hot Stocks
Bain Capital Specialty Finance expands board to 7 directors from 5 directors »

Bain Capital Specialty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

SYF

Synchrony

$36.09

0.54 (1.52%)

, PYPL

PayPal

$119.87

1.07 (0.90%)

08:35
07/19/19
07/19
08:35
07/19/19
08:35
Hot Stocks
Synchrony says average active accounts up 9% in Q2 »

Synchrony (SYF) says it…

SYF

Synchrony

$36.09

0.54 (1.52%)

PYPL

PayPal

$119.87

1.07 (0.90%)

WMT

Walmart

$114.68

0.08 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 24

    Jul

  • 15

    Aug

  • 25

    Sep

  • 13

    Nov

SMSI

Smith Micro

$3.12

0.04 (1.30%)

08:35
07/19/19
07/19
08:35
07/19/19
08:35
Initiation
Smith Micro initiated  »

B. Riley FBR starts Smith…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

UNP

Union Pacific

$174.15

10.1 (6.16%)

08:35
07/19/19
07/19
08:35
07/19/19
08:35
Recommendations
Union Pacific analyst commentary  »

Union Pacific price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

MRKR

Marker Therapeutics

$8.68

-0.01 (-0.12%)

08:35
07/19/19
07/19
08:35
07/19/19
08:35
Conference/Events
Marker Therapeutics to hold a conference call »

Management reviews data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 09

    Sep

AMRS

Amyris

$2.91

-0.03 (-1.02%)

08:35
07/19/19
07/19
08:35
07/19/19
08:35
Hot Stocks
Amyris expands contract with ADL Bionatur to 2020 »

Amyris has expanded its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

DHR

Danaher

$143.03

3.43 (2.46%)

08:34
07/19/19
07/19
08:34
07/19/19
08:34
Recommendations
Danaher analyst commentary  »

Danaher price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

STAF

Staffing 360 Solutions

$1.74

0.025 (1.46%)

08:32
07/19/19
07/19
08:32
07/19/19
08:32
Hot Stocks
Staffing 360 Solutions opens new office in Shelton, Connecticut »

Staffing 360 Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RGLD

Royal Gold

$117.56

4.19 (3.70%)

08:32
07/19/19
07/19
08:32
07/19/19
08:32
Recommendations
Royal Gold analyst commentary  »

Royal Gold price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

HBAN

Huntington Bancshares

$13.76

0.18 (1.33%)

08:32
07/19/19
07/19
08:32
07/19/19
08:32
Hot Stocks
Huntington Bancshares increases quarterly cash dividend 7% to 15c per share »

Huntington Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 29

    Aug

PETX

Aratana Therapeutics

$4.93

(0.00%)

08:30
07/19/19
07/19
08:30
07/19/19
08:30
Options
One option delisting on July 19th »

Option delistings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCK

Crown Holdings

$59.50

0.12 (0.20%)

08:29
07/19/19
07/19
08:29
07/19/19
08:29
Recommendations
Crown Holdings analyst commentary  »

Crown Holdings shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBIO

Harvard Bioscience

$1.78

0.03 (1.71%)

08:29
07/19/19
07/19
08:29
07/19/19
08:29
Recommendations
Harvard Bioscience analyst commentary  »

Harvard Bioscience CFO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HON

Honeywell

$173.86

5.05 (2.99%)

08:28
07/19/19
07/19
08:28
07/19/19
08:28
Recommendations
Honeywell analyst commentary  »

Honeywell price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 06

    Aug

TSM

TSMC

$43.21

1.59 (3.82%)

08:28
07/19/19
07/19
08:28
07/19/19
08:28
Upgrade
TSMC rating change  »

TSMC upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$361.17

-8.28 (-2.24%)

08:26
07/19/19
07/19
08:26
07/19/19
08:26
Recommendations
Boeing analyst commentary at Jefferies »

Boeing price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

BX

Blackstone

$45.66

0.39 (0.86%)

08:25
07/19/19
07/19
08:25
07/19/19
08:25
Recommendations
Blackstone analyst commentary  »

Blackstone price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

$DJT

DJ Transportation Average

$0.00

(0.00%)

08:20
07/19/19
07/19
08:20
07/19/19
08:20
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJU

DJ Utility Average

$0.00

(0.00%)

08:20
07/19/19
07/19
08:20
07/19/19
08:20
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

08:20
07/19/19
07/19
08:20
07/19/19
08:20
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.